ProQR Therapeutics (PRQR) Net Income towards Common Stockholders (2012 - 2026)
ProQR Therapeutics (PRQR) posted quarterly Net Income towards Common Stockholders of -$15.2 million for Q1 2026, down 32.78% year-on-year from -$22.7 million in Q1 2025, and down 70.61% on a QoQ basis from -$8.9 million in Q4 2025.
ProQR Therapeutics (PRQR) Net Income towards Common Stockholders (2012 - 2026) Analysis & Trends
ProQR Therapeutics (PRQR) has reported Net Income towards Common Stockholders for 15 consecutive years, with -$15.2 million the latest figure, recorded in Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 32.78% year-over-year to -$15.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$51.3 million (down 48.12% YoY) and the FY2025 annual result came in at -$48.0 million, down 51.94% from the prior year.
- Net Income towards Common Stockholders declined to -$15.2 million in Q1 2026 per PRQR's latest filing, from -$8.9 million in the prior quarter.
- Over the last five years, Net Income towards Common Stockholders for PRQR reached as high as -$3.1 million in Q2 2024 and fell as low as -$26.5 million in Q3 2022.
- A 5-year average of -$11.8 million and a median of -$10.5 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders soared 74.08% — and 2025, when it tumbled 377.75%.
- Year by year, Net Income towards Common Stockholders stood at -$15.1 million in 2022, then soared by 62.88% to -$5.6 million in 2023, then slumped by 86.47% to -$10.5 million in 2024, then grew by 14.78% to -$8.9 million in 2025, then slumped by 70.61% to -$15.2 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$15.2 million, -$8.9 million, and -$12.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -0.68 |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | ProQR Therapeutics | 185.44 Mn | 93.15 Mn | - | -15.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.23 Mn |
| Dec 31, 2025 | -8.93 Mn |
| Sep 30, 2025 | -12.55 Mn |
| Jun 30, 2025 | -14.64 Mn |
| Mar 31, 2025 | -11.47 Mn |
| Dec 31, 2024 | -10.47 Mn |
| Sep 30, 2024 | -9.66 Mn |
| Jun 30, 2024 | -3.06 Mn |
| Mar 31, 2024 | -8.71 Mn |
| Dec 31, 2023 | -5.62 Mn |
| Sep 30, 2023 | -6.88 Mn |
| Jun 30, 2023 | -9.10 Mn |
| Mar 31, 2023 | -10.41 Mn |
| Dec 31, 2022 | -15.13 Mn |
| Sep 30, 2022 | -26.53 Mn |
| Jun 30, 2022 | -15.59 Mn |
| Mar 31, 2022 | -16.06 Mn |
| Dec 31, 2021 | -20.73 Mn |
| Sep 30, 2021 | -17.12 Mn |
| Jun 30, 2021 | -18.08 Mn |